315 related articles for article (PubMed ID: 26267728)
1. Erythema of Rosacea: Validation of Patient's Self-Assessment Grading Scale.
Tan J; Leoni M
J Drugs Dermatol; 2015 Aug; 14(8):841-4. PubMed ID: 26267728
[TBL] [Abstract][Full Text] [Related]
2. Brimonidine gel 0.33% rapidly improves patient-reported outcomes by controlling facial erythema of rosacea: a randomized, double-blind, vehicle-controlled study.
Layton AM; Schaller M; Homey B; Hofmann MA; Bewley AP; Lehmann P; Nohlgård C; Sarwer DB; Kerrouche N; Ma YM
J Eur Acad Dermatol Venereol; 2015 Dec; 29(12):2405-10. PubMed ID: 26416154
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double-blind, and vehicle-controlled pivotal studies.
Fowler J; Jackson M; Moore A; Jarratt M; Jones T; Meadows K; Steinhoff M; Rudisill D; Leoni M
J Drugs Dermatol; 2013 Jun; 12(6):650-6. PubMed ID: 23839181
[TBL] [Abstract][Full Text] [Related]
4. Once-daily topical brimonidine tartrate gel 0·5% is a novel treatment for moderate to severe facial erythema of rosacea: results of two multicentre, randomized and vehicle-controlled studies.
Fowler J; Jarratt M; Moore A; Meadows K; Pollack A; Steinhoff M; Liu Y; Leoni M;
Br J Dermatol; 2012 Mar; 166(3):633-41. PubMed ID: 22050040
[TBL] [Abstract][Full Text] [Related]
5. Improvement in facial erythema within 30 minutes of initial application of brimonidine tartrate in patients with rosacea.
Jackson JM; Fowler J; Moore A; Jarratt M; Jones T; Meadows K; Steinhoff M; Rudisill D; Leoni M;
J Drugs Dermatol; 2014 Jun; 13(6):699-704. PubMed ID: 24918560
[TBL] [Abstract][Full Text] [Related]
6. Reliability of Clinician Erythema Assessment grading scale.
Tan J; Liu H; Leyden JJ; Leoni MJ
J Am Acad Dermatol; 2014 Oct; 71(4):760-3. PubMed ID: 24999270
[TBL] [Abstract][Full Text] [Related]
7. Treatment of facial erythema in patients with rosacea with topical brimonidine tartrate: correlation of patient satisfaction with standard clinical endpoints of improvement of facial erythema.
Fowler J; Tan J; Jackson JM; Meadows K; Jones T; Jarratt M; Leoni M;
J Eur Acad Dermatol Venereol; 2015 Mar; 29(3):474-81. PubMed ID: 25074756
[TBL] [Abstract][Full Text] [Related]
8. Rosacea or photodamaged skin? Use of brimonidine gel in differentiating erythema in the two conditions.
Oon HH; Lim ZV
Australas J Dermatol; 2017 Feb; 58(1):63-64. PubMed ID: 26763464
[TBL] [Abstract][Full Text] [Related]
9. Facial Erythema of Rosacea - Aetiology, Different Pathophysiologies and Treatment Options.
Steinhoff M; Schmelz M; Schauber J
Acta Derm Venereol; 2016 Jun; 96(5):579-86. PubMed ID: 26714888
[TBL] [Abstract][Full Text] [Related]
10. Comparative pharmacokinetics and bioavailability of brimonidine following ocular and dermal administration of brimonidine tartrate ophthalmic solution and gel in patients with moderate-to-severe facial erythema associated with rosacea.
Benkali K; Leoni M; Rony F; Bouer R; Fernando A; Graeber M; Wagner N
Br J Dermatol; 2014 Jul; 171(1):162-9. PubMed ID: 24506775
[TBL] [Abstract][Full Text] [Related]
11. Topical brimonidine tartrate 0·33% gel effectively reduces the post-treatment erythema of daylight-activated photodynamic therapy.
Gerber PA
Br J Dermatol; 2016 Jun; 174(6):1422-3. PubMed ID: 26727630
[No Abstract] [Full Text] [Related]
12. Efficacy and safety of oxymetazoline cream 1.0% for treatment of persistent facial erythema associated with rosacea: Findings from the 52-week open label REVEAL trial.
Draelos ZD; Gold MH; Weiss RA; Baumann L; Grekin SK; Robinson DM; Kempers SE; Alvandi N; Weng E; Berk DR; Ahluwalia G
J Am Acad Dermatol; 2018 Jun; 78(6):1156-1163. PubMed ID: 29409914
[TBL] [Abstract][Full Text] [Related]
13. Paradoxical Erythema Reaction of Long-term Topical Brimonidine Gel for the Treatment of Facial Erythema of Rosacea.
Lowe E; Lim S
J Drugs Dermatol; 2016 Jun; 15(6):763-5. PubMed ID: 27272086
[TBL] [Abstract][Full Text] [Related]
14. Allergic contact dermatitis caused by Mirvaso®, brimonidine tartrate gel 0.33%, a new topical treatment for rosaceal erythema.
Cookson H; McFadden J; White J; White IR
Contact Dermatitis; 2015 Dec; 73(6):366-7. PubMed ID: 26768997
[No Abstract] [Full Text] [Related]
15. Treatment of erythemato-telangiectatic rosacea with brimonidine alone or combined with vascular laser based on preliminary instrumental evaluation of the vascular component.
Micali G; Dall'Oglio F; Verzì AE; Luppino I; Bhatt K; Lacarrubba F
Lasers Med Sci; 2018 Aug; 33(6):1397-1400. PubMed ID: 28889348
[TBL] [Abstract][Full Text] [Related]
16. Brimonidine tartrate for the treatment of facial flushing and erythema in rosacea.
Tong LX; Moore AY
Expert Rev Clin Pharmacol; 2014 Sep; 7(5):567-77. PubMed ID: 25091290
[TBL] [Abstract][Full Text] [Related]
17. Brimonidine for erythema caused by rosacea.
Drug Ther Bull; 2014 Dec; 52(12):138-40. PubMed ID: 25505014
[TBL] [Abstract][Full Text] [Related]
18. Pivotal Trial of the Efficacy and Safety of Oxymetazoline Cream 1.0% for the Treatment of Persistent Facial Erythema Associated With Rosacea: Findings from the First REVEAL Trial.
Kircik LH; DuBois J; Draelos ZD; Werschler P; Grande K; Cook-Bolden FE; Weng E; Berk DR; Ahluwalia G
J Drugs Dermatol; 2018 Jan; 17(1):97-105. PubMed ID: 29320594
[TBL] [Abstract][Full Text] [Related]
19. [Erythema of rosacea: a new and effective treatment].
Hougeir FG
Ann Dermatol Venereol; 2014 Sep; 141 Suppl 2():S169-74. PubMed ID: 25151933
[TBL] [Abstract][Full Text] [Related]
20. Clinical Pharmacokinetics of Oxymetazoline Cream Following Topical Facial Administration for the Treatment of Erythema Associated With Rosacea.
Kuang AW; DuBois J; Attar M; Ahluwalia G
J Drugs Dermatol; 2018 Feb; 17(2):213-220. PubMed ID: 29462230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
